Sankhyan, Anurag and Sharma, Chandresh and Dutta, Durgashree and Sharma, Tarang and Chosdol, Kunzang and Wakita, Takaji and Watashi, Koichi and Awasthi, Amit and Acharya, Subrat K and Khanna, Navin and Tiwari, Ashutosh and Sinha, Subrata (2016) Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals. Scientific Reports, 6. p. 21240.
Text
9_Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals.pdf Restricted to Registered users only Download (1852Kb) |
Abstract
Neutralizing monoclonal antibodies are being found to be increasingly useful in viral infections. In hepatitis B infection, antibodies are proven to be useful for passive prophylaxis. The preS1 region (21–47a.a.) of HBV contains the viral hepatocyte-binding domain crucial for its attachment and infection of hepatocytes. Antibodies against this region are neutralizing and are best suited for immune-based neutralization of HBV, especially in view of their not recognizing decoy particles. Anti-preS1 (21–47a.a.) antibodies are present in serum of spontaneously recovered individuals. We generated a phage-displayed scFv library using circulating lymphocytes from these individuals and selected four preS1-peptide specific scFvs with markedly distinct sequences from this library. All the antibodies recognized the blood-derived and recombinant preS1 containing antigens. Each scFv showed a discrete binding signature, interacting with different amino acids within the preS1-peptide region. Ability to prevent binding of the preS1 protein (N-terminus 60a.a.) to HepG2 cells stably expressing hNTCP (HepG2-hNTCP-C4 cells), the HBV receptor on human hepatocytes was taken as a surrogate marker for neutralizing capacity. These antibodies inhibited preS1-hepatocyte interaction individually and even better in combination. Such a combination of potentially neutralizing recombinant antibodies with defined specificities could be used for preventing/managing HBV infections, including those by possible escape mutants.
Item Type: | Article |
---|---|
Subjects: | Neuro-Oncological Disorders Genetics and Molecular Biology |
Depositing User: | Dr. D.D. Lal |
Date Deposited: | 04 May 2017 05:42 |
Last Modified: | 09 Dec 2021 09:26 |
URI: | http://nbrc.sciencecentral.in/id/eprint/36 |
Actions (login required)
View Item |